Mylan has reported earnings of $499.1 million in its third quarter.
On a per-share basis, the Canonsburg, Pennsylvania-based company said it had profit of $1.26. Earnings, adjusted for one-time gains and costs, came to $1.16 per share.
The results surpassed Wall Street expectations. The average estimate of analysts surveyed by Zacks Investment Research was for earnings of $1.14 per share.
The generic drugmaker posted revenue of $2.08 billion in the period, also exceeding Street forecasts. Analysts expected $2.07 billion, according to Zacks.
For the current quarter ending in December, Mylan expects its per-share earnings to range from $1.03 to $1.09.
The company expects full-year earnings in the range of $3.54 to $3.60 per share, with revenue ranging from $7.7 billion to $7.8 billion.
Mylan shares have climbed 21 percent since the beginning of the year, while the Standard & Poor’s 500 index has increased almost 8 percent. In the final minutes of trading on Thursday, shares hit $52.37, a rise of 36 percent in the last 12 months.
